Aboleris Pharma bags €27.3m in Series A Financing
Autoimmunity specialist AbolerIS Pharma will use a €27.3m Series A Financing to advance its first-in-class antibody inducing immune tolerance in rheumatoid arthritis into the clinic.
ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Autoimmunity specialist AbolerIS Pharma will use a €27.3m Series A Financing to advance its first-in-class antibody inducing immune tolerance in rheumatoid arthritis into the clinic.
The Cultivated B ist the first company in the world to apply for EU-Novel-Food authorisation of a hotdog made from plant protein and cultivated muscle cells.
A Belgian-British research team has identified the human protein underlying necroptosis of human brain cells in Alzheimer’s mice and stopped cell death.
French pharma company Pierre Fabre Laboratories has baged Vertical Bio to push development of the companys NSCLC candidate.
C
French-US-based investment specialist Lauxera Capital Partners announced today that it has invested €17m in Swedish cell culture company BioLamina AB (BioLamina)
At a council meeting, a majority of EU agriculture ministers have supported the draft regulation on new genomic technologies (NGT) proposed by the EU Commission in early July.
German researchers have developed a new way to detect the about 300 cullin-RING ligases (CRLs) which specifically trigger destruction of specific proteins in the cell.
According to Swiss bioethicists, deregulation of genetic engineering rules for plants optimised through targeted mutation and cisgenetics will make little contribution to climate protection by 2050.
CAR-T therapies represent a new successful strategy for the treatment of hematological malignancies; however, recent studies have revealed some limitations, including the occurrence of graft-versus-host disease (GVHD), neurotoxicity, and cytokine release syndromes (CRS). This has prompted researchers to look for alternative, safer cells, such as natural killer (NK) cells 1. NK cells are lymphocytes that kill tumor cells and virus-infected cells non-specifically, without prior sensitization. CAR-NK therapy involves the modification of NK cells with mature chimeric antigen receptor (CAR) technology to exploit their unique target cell recognition mechanism and broad tumor-killing ability. Figure 1 illustrates the CAR-NK therapeutic strategy 1. Compared with CAR-T therapy, CAR-NK therapy has numerous advantages, such as lower GVHD and significantly reduced CRS toxicity and immune effector cell-associated neurotoxicity syndrome toxicity, which enhance overall safety 2, 3. In addition, NK cells have multiple tumor recognition sites, thus potentially reducing antigenic escape failure 4.
The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have entered into a strategic partnership to accelerate the development of globally accessible vaccines against endemic outbreaks.